NI-2601 / LightChain Bioscience - LARVOL DELTA

NI-2601, an Fc-active CD47xPD-L1 bispecific antibody that selectively targets CD47 on PD-L1-positive tumors (AACR 2022) - P1, P1b | "The latter is also used in our CD47xCD19 bispecific antibody NI-1701/TG-1801, currently in phase I clinical trials (NCT03804996, NCT04806035)...NI-2601 demonstrated effective blockade of PD-1/PD-L1 interaction, and T-cell activation in vitro, similar to the anti-PD-L1 clinical benchmarks atezolizumab and avelumab...Thus, NI-2601 is able to harness Fc-effector function to eliminate PD-L1-positive tumor cells while sparing PD-L1-negative cells, such as RBC or platelets. Pharmacokinetic and tolerability studies in non-human primate are planned for 2022."

IO biomarker • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • CD47 • SIRPA

"#LightChainBioscience reported at #AACR22 #NI2601 & #NI2901 #CD47xPDL1 #BispecificAntibodies https://t.co/WppsKybJ9X" (,@1stOncology)

Oncology

"#LightChainBioscience to present at #SITC21 #NI2601 & #NI2901 #BispecificAntibody programs https://t.co/5aM6onnzv5" (,@1stOncology)

Oncology